Kornimate/medical-research-clean huggingface dataset:
using artificial intelligence for the detection of respiratory diseases associated with pollution

Conditions: COPD Asthma; Lung Neoplasm; Emphysema

Summary: generating a picture at the city level, through geospatial and temporal grouping a lung diseases associated or exacerbated by pollution (copd, ab and neoplasm pulmonary or pleural) and correlating this data with pollution data. development of an accurate and prognostic hrct imaging diagnostic tool, computer assisted in the mentioned pathology, by generating an algorithm capable of to detect early the follow-up tomographic imaging lesions, as well as to evaluate objective their speed of evolution. validation of the proposed algorithm by comparison with medical diagnosis.


Eligibility criteria:
inclusion criteria: * patients must be diagnosed with copd and/or asthma and/or pulmonary neoplasm and/or secondary pulmonary, pleural or mediastinal determinations, suspected or confirmed, according to icd-10. * patients will be included regardless of the type of hospitalization, continuous or day. * the existence of freely expressed consent, carried out according to ethics standards professional (from the observation sheet). for stage 2 * the use of hrct images, in dicom format, with a maximum cup thickness of 1.5 mm and with an average of 250 cups; no image acquisition errors; * imaging monitoring at a time interval;. * respiratory function evaluation data available: spirometry +/- the factor of gaseous diffusion (dlco); exclusion criteria: for both stages: - patients who do not have a stable real domicile (eg social cases) or are not from the timis county for stage 2 * patients who do not have hrct images available or cannot be followed. * patients who have insufficient quality hrct images. * patients who have a history of lung surgery. * patients who have a history of allergies to contrast agents used in imaging hrct.

Keywords: complex networks lung imaging spectral analysis geolocation
what is the effect of a course for treatment providers on their patient outcome

Conditions: Pain

Summary: the goal is to acquire more in-depth knowledge on physical therapists' attitudes towards and beliefs about psychosocial factors in back pain, how physical therapists integrate psychosocial factors into their clinical practice and the effects of a training program for physical therapists in psychosocial factors on clinical practice and thereby on patient outcome in terms of disability, pain, catastrophizing, and treatment satisfaction.

neck and back pain continue to be extremely common, with a high prevalence and wide socio-economic consequences all over the industrialized world. through the years a growing interest has risen for other factors than the pure biomedical or biomechanical. this has led to a new clinical model for the treatment of back pain; the biopsychosocial model of illness. treatment based on the biopsychosocial model not only must address the biological basis of symptoms, but must incorporate the full range of social and psychological factors that have been shown to affect pain, distress and disability. since there is today strong evidence indicating that psychosocial factors have a greater impact on disability then biomechanical or biomedical factors and strong evidence that psychosocial factors are strongly linked to the transition from acute to chronic pain, concept of psychosocial risk factors has been developed. although the concept of psychosocial risk factors still is relatively new, there seems to be an international consensus about the importance of psychosocial risk factors for the prevention of the development of chronic pain but there appears to be considerable uncertainty about the clinical application. health care providers' (hcps') attitudes and beliefs appear to influence the information they provide to patients. this may subsequently result in different patient outcome depending on the hcps' attitudes and beliefs. physical therapists attitudes and beliefs are relatively unexplored but seem to have an effect on patients' attitudes and beliefs, which can affect patient outcome in terms of sick leave, health care use and function. hcp attitudes and beliefs towards psychosocial factors are relatively unexplored. yet, it seems physical therapists do not necessarily accept new evidence-based information and may have difficulties in applying evidence-based information in their clinical practice. implementation and dissemination of evidence-based psychosocial factors requires favourable attitudes, knowledge and skills to ensure a behavioural change on behave of the physical therapists.

Eligibility criteria:
inclusion criteria: * musculoskeletal pain, * age between 18 and 65 exclusion criteria: * sick leave for more than 3 months during the past year as a result of present the musculoskeletal pain problem

Keywords: physical therapy, musculoskeletal pain, psychosocial factors, dissimilation, evidence based, education
pain in competitive athletes with physical disabilities: techniques, support and perceived difficulties

Conditions: Pain; Athletes; Physical Disability

Summary: pain in physically disabled athletes affects the sporting career directly or indirectly through psychological consequences. numerous studies address psychological skills in able-bodied athletes and in able-bodied athletes they are scarce.this information is part of a research project aimed at finding resources to help athletes in their pain management.

the purpose of this study is to determine how competitive athletes perceive how pain can affect their sporting careers; what techniques and/or strategies athletes use for pain management and how useful these are; to determine the extent to which athletes with disabilities have received support for pain management and to what extent they have found it useful; and to determine the difficulties they often face in managing their pain.the aim of this questionnaire is to find out how pain, resulting from injury, can affect the sporting careers of competitive athletes with physical disabilities and what techniques they use to manage it.

Eligibility criteria:
inclusion criteria: athletes: * competitive athletes. * physical disability. * age without criteria. exclusion criteria: * failure to meet the inclusion criteria.

Keywords: athlete physical disability chronic pain psychological models
docetaxel in treating children with relapsed or refractory acute lymphoblastic or acute myeloid leukemia

Conditions: Leukemia

Summary: rationale: drugs used in chemotherapy, such as docetaxel, work in different ways to stop cancer cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of docetaxel in treating children who have relapsed or refractory acute lymphoblastic or acute myeloid leukemia.

objectives: * determine the response rate in pediatric patients with relapsed or refractory acute lymphoblastic or acute myeloid leukemia treated with docetaxel. * determine the toxicity of this regimen in these patients. outline: patients receive docetaxel iv over 1 hour on days 1, 8, and 15. treatment repeats every 28 days for a maximum of 12 courses in the absence of disease progression or unacceptable toxicity. projected accrual: a total of 10-20 patients will be accrued for this study within 1 year.

Eligibility criteria:
disease characteristics: * histologically confirmed acute lymphoblastic or acute myeloid leukemia * m3 bone marrow relapse required * refractory to conventional chemotherapy * no extramedullary disease at relapse patient characteristics: age: * 21 and under at time of initial diagnosis performance status: * ecog 0-2 life expectancy: * at least 2 months hematopoietic: * not specified hepatic: * bilirubin no greater than 1.5 mg/dl * ast and alt no greater than 1.5 times normal * alkaline phosphatase no greater than 2.5 times normal renal: * creatinine no greater than 1.5 times normal or * creatinine clearance or radioisotope glomerular filtration rate at least 70 ml/min other: * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception prior concurrent therapy: biologic therapy: * at least 7 days since prior biologic therapy and recovered * at least 6 months since prior allogeneic stem cell transplantation * no concurrent immunomodulating agents during first 2 courses of therapy * no concurrent routine filgrastim (g-csf) chemotherapy: * see disease characteristics * at least 2 weeks since prior chemotherapy (4 weeks for nitrosoureas) and recovered * no prior paclitaxel or docetaxel * no other concurrent chemotherapy during first 2 courses of therapy endocrine therapy: * no concurrent corticosteroid therapy except dexamethasone, low-dose hydrocortisone to treat allergic reactions, or treatment for adrenal crisis radiotherapy: * recovered from prior radiotherapy * at least 2 weeks since prior palliative local radiotherapy * at least 6 months since prior craniospinal radiotherapy or radiotherapy to at least 50% of the pelvis * at least 6 weeks since prior substantial bone marrow radiotherapy * no concurrent radiotherapy surgery: * not specified

Keywords: recurrent childhood acute lymphoblastic leukemia recurrent childhood acute myeloid leukemia childhood acute promyelocytic leukemia (m3)
effectiveness of bupropion in treating marijuana dependent individuals

Conditions: Marijuana Abuse; Substance-Related Disorders

Summary: a definable and significant withdrawal syndrome occurs upon cessation of chronic, heavy marijuana use. bupropion (zyban) is a medication currently used to treat withdrawal symptoms associated with tobacco use. the purpose of this study is to determine if bupropion will help individuals stop using marijuana.

a definable and significant withdrawal syndrome occurs upon cessation of chronic, heavy marijuana use. this syndrome includes alterations in mood, sleep disturbances, and cognitive performance. many of nicotine's withdrawal symptoms are similar to those observed with marijuana withdrawal. bupropion has been shown to be effective in treating nicotine addiction.the purpose of this study is to determine if bupropion is effective in treating marijuana dependent individuals. specifically, this study will determine if bupropion alleviates withdrawal symptoms associated with marijuana abuse. participants in this 21-day, double-blind study will be randomly assigned to receive either bupropion or placebo. treatment with bupropion will occur for one week before stopping marijuana use (quit day). bupropion will be administered at 150 mg per day for 3 days, followed by 300 mg per day for the remainder of the study. quit day will occur on day 8, at which time participants will be required to remain abstinent from marijuana for the duration of the study. participants will provide daily urine specimens. changes in vigilance, memory, reaction time, and psychomotor performance as well as withdrawal symptoms will be evaluated.

Eligibility criteria:
inclusion criteria: * current marijuana use and dependence * marijuana use of at least 5 times in the past 7 days or more than 25 times per month for the 3 years prior to enrollment * unsuccessful in a previous attempt to quit marijuana exclusion criteria: * axis i disorder * any drug abuse or dependence other than marijuana * currently taking antipsychotic or antidepressant medication * heavy alcohol drinker (more than 20 drinks per week) * current nicotine dependence * history of a seizure disorder * current or prior eating disorder (e.g., bulimia or anorexia nervosa) * heavy caffeine use (more than 300 mg per day) * life threatening or unstable medical illness * pregnant

Keywords: marijuana treatment
lipid biomarkers for diabetic heart disease

Conditions: Type II Diabetes Mellitus; Diabetes Complications

Summary: this study will test whether lowering the delivery of excess fats to the heart in persons with type-2 diabetes mellitus improves heart muscle function. the investigators will also test whether specific lipid molecular species in plasma can serve as biomarkers for diabetic heart disease.

screening procedures include 12-hour fasting blood draw, urine pregnancy testing for females, completion of medical history questionnaire, and stress echocardiography to rule out coronary artery disease or cardiomyopathy. subjects who meet screening criteria will return for visit 2, which consists of a urine collection, 12-hour fasting blood draw, dual-energy x-ray absorptiometry (dxa) for body composition, magnetic resonance spectroscopy analysis of the liver, and resting echocardiogram for analysis of heart structure and function. subjects will then be randomized to treatment with fenofibrate (160 mg/d) or an identical-appearing placebo for 12 weeks. they will be asked to continue their usual medications, diet and physical activity. subjects will receive a pedometer to wear daily to track their physical activity. subjects will meet with dietitians from the lifestyle intervention core to complete a 24-hour dietary recall. they will be instructed to record their daily blood glucose concentrations, distance walked and any side effects, illnesses or stresses in a study-supplied log. subjects will be instructed to either email or fax the log to the study coordinator each week (or discuss by phone). subjects will return 6 weeks after starting intervention for visit 3 to ensure their medical safety. procedures at this visit include an interim medical history, urine pregnancy test for females, blood draw to rule out untoward effects of the study drug on liver or kidney function, pill count to assess compliance, review of logs of blood glucose, distance walked, and side effects, illnesses or stresses, and meeting with a dietitian for a 24-hour dietary recall. subjects will continue to take their study medication/placebo and keep logs of blood glucose levels, distance walked, and side effects, illnesses and stresses for another 6 weeks. they will return for visit 4 after 12 total weeks of intervention. visit 4 involves a urine collection, 12-hour fasting blood draw, review of subject logs, pill count, and 24-hour dietary recall. in addition, magnetic resonance spectroscopy analysis of the liver and resting echocardiogram analysis of the heart will be performed to determine if there have been any changes in liver fat or heart function during the 12-week intervention.

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus exclusion criteria: * body weight \> 300 lb. * hiv * hypothyroid * steroid medication, fenofibrate * smoking * bp \> 140/90 * heart disease * pregnant or lactating * consumption of \> 5 alcoholic drinks/wk * creatinine \> 1.5 mg/dl * hematocrit \< 28

Keywords: diabetes diabetic cardiomyopathy triglycerides
safety of gastric volume emptying after the intake of maltodextrin and glutamine

Conditions: Pulmonary Aspiration of Gastric Contents; Adverse Effects in the Therapeutic Use of Other and Unspecified General Anaesthetics; Pulmonary Aspiration During Anaesthetic Induction

Summary: carbohydrates (cho)-based drinks 2h before the induction of anesthesia are recommended to decrease insulin resistance. the addition of glutamine (gln) in these beverages may enhance the benefits of cho alone. however, only a few studies tested the safety of this formula. the objective of this study was to evaluate the gastric residual volume (grv) after the intake of a beverage containing cho plus gln using magnetic resonance (mri).

we included 11 male young volunteers (aged between 21 and 30 years-old) with body mass index (bmi) between 20 and 29 kg/m2 and without either acute or chronic illness in the last 3 months. the criteria for exclusion were non-adherence to any phase of the study protocol, gastroesophageal reflux disease, previous history of intolerance to lactose, gastroparesis or history of poor gastric emptying, diabetes mellitus, and previous abdominal surgery. each volunteer was randomized for participation in the study in a blind fashion. all subjects underwent two different protocols before mri with an interval of seven days between them. both phases took place after an overnight fast of eight hours. the volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00am and 200ml (2 hours before the exam was carried out) at 10:00am of a beverage containing either water plus 12.5% maltodextrin (phloraceae, cuiabá, brazil; cho group) or the same beverage plus 15g of gln (phloraceae, cuiabá, brazil; gln group). the participants were instructed not to ingest alcohol, medication, and caffeine within 24 hours of the study, nor do any vigorous physical activity during that time. in both phases the individuals were blind to the specific drink and they were told to ingest the beverage in a maximum period of five minutes and t0 was defined as the moment they complete the intake of the solution.the powdered products (maltodextrin alone or maltodextrine plus glutamine) were packed in coded opaque sachets and the content was only known by the pharmacist who manipulated it. all the participants in the study underwent magnetic resonance of the upper abdomen at 12:00am and 01:00pm. the grv observed during the first exam was defined as t120 and the second exam as t180. all exams were performed by the same magnetic resonance equipment (intera 1.5t ; philips healthcare, eindhoven, holland).

Eligibility criteria:
inclusion criteria: * young male volunteers (aged between 21 and 30 years-old) with body mass index (bmi) between 20 and 29 kg/m2 and without either acute or chronic illness in the last 3 months. exclusion criteria: * non-adherence to any phase of the study protocol, * gastroesophageal reflux disease, * previous history of intolerance to lactose, * gastroparesis or history of poor gastric emptying, * diabetes mellitus, and * previous abdominal surgery

Keywords: preoperative care maltodextrine glutamine gastric residual volume mri
histochemical study of vitiligo in sohag university hospital patients

Conditions: Vitiligo

Summary: vitiligo is a common acquired idiopathic disorder characterized by depigmentation of the skin, hair, and mucous membranes in the form of macules and patches due to selective melanocyte destruction . incidence of vitiligo is about 0.5% to 2% of the world's population, and its incidence continues to increase. vitiligo can appear at any age group especially in the second and third decades of life. about one-third of vitiligo patients are children under ten years old vitiligo can be classified into non-segmental, segmental, mixed and unclassifiable/undetermined types. vitiligo has a negative impact on patient's quality of life by decreasing their self-confidence and causing significant psychological distress.

the pathogenesis of vitiligo is still unclear but some theories can explain it such as oxidative stress, autoimmunity, autocytotoxicity, genetic factors, neural and melanocytorrhagy . loss of pigment which occur in vitiligo may be due to two main causes: absence of melanocytes and/or the inability of melanocytes to produce and store melanin in melanosomes in the process of melanogenesis. high mobility group box protein b1 (hmgb1) normally presents in the nucleus to maintain genomic stabilization and regulate gene transcription. but, hmgb1 can be released outside the cell due to exposure to stressful factors such as oxidative stress and function as a damage-associated molecular pattern (damp) protein leading to strong proinflammatory effects. recent data showed that hmgb1 is overexpressed in both blood and lesional specimens from vitiligo patients. moreover, oxidative stress triggers the release of hmgb1 from keratinocytes and melanocytes, indicating that hmgb1 may participate and play a crucial role in the pathological process of vitiligo. hmgb1 directly induces melanocyte apoptosis through stimulation with reactive oxidative stress (ros) or ultraviolet b (uvb) in vitro which significantly increases the release of hmgb1 from keratinocytes, which inhibits the expression of melanogenesis-related molecules such as microphthalmia- associated transcription factor (mitf), tyrosinase-related proteins and the gp100 protein in a paracrine manner and finally activate caspase-3 to trigger melanocyte apoptosis

Eligibility criteria:
inclusion criteria: * the study will include patients with vitiligo aged 18-50 years old. exclusion criteria: * pregnancy * lactation * patient on immunosuppressive treatment for vitiligo over the last month * skin diseases, other than vitiligo. * systemic diseases particulary endocrine disorders and autoimmune connective tissue diseases.

Keywords: vitiligo autoimmunity apoptosis melanocytes
comparison of analgesic duration of popliteal block versus ankle block in patients undergoing forefoot surgery

Conditions: Pain, Postoperative

Summary: pain after forefoot surgery can be important and regional anesthesia plays a crucial role in post-operative pain control. several techniques can be used to achieve surgical anesthesia as well as postoperative analgesia. of those techniques the ankle block and sciatic nerve block at the popliteal fossa are the most common. the primary goal of this study is thus to compare the analgesic duration of these two types of blocks for patients undergoing forefoot surgery.

patients scheduled for unilateral forefoot surgery, aged over 18 years old and asa status i-iii without any contra-indications for regional anesthesia will be enrolled. after a standard randomisation, patients will be allocated in either of two groups : ankle block or sciatic nerve block at the popliteal fossa. in both groups the patients will have a multimodal analgesic regimen followed by a patient-controlled-analgesia (pca) of morphine. the primary endpoint is the analgesic duration, defined by the time between the end of the block procedure and the first iv request of morphine from a pca.

Eligibility criteria:
inclusion criteria: * patients who are going to undergo a unilateral forefoot surgery ; * asa i-iii ; * aged 18 years or more; * weighing at least 45 kg exclusion criteria: * patient refusal and/or language/cognitive barrier * pregnancy * contra-indication for regional anesthesia * opiate or alcohol dependency * concomitant oncological disease with chemotherapy * patients suffering from neuropathic pain
efficacy and safety of lcz696a in patients with essential hypertension

Conditions: Hypertension

Summary: this study was a dose-ranging efficiacy study in patients with essential hypertension to assess the blood pressure lowering effect, and safety of lcz696 compared to valsartan and placebo. the study will also evaluate the efficacy and safety of ahu377 as compared to placebo.


Eligibility criteria:
inclusion criteria: * male or females from 18 up to and including 75 years * patients with mild-to-moderate uncomplicated essential hypertension, untreated or currently taking antihypertensive therapy (monotherapy or combination therapy of 2 drugs; therapy with a fixed dose combination of two active substances represents 2 drugs) * untreated patients must have had an office msdbp≥ 95 mmhg at the randomization visit (visit 3) and the 2 preceding visits (visits 1 and 2). * treated patients must have had an office msdbp≥ 90 mmhg after washout (visit 2), and a msdbp\> 95 mmhg at baseline (visit 3); exclusion criteria: * severe hypertension (mssbp ≥180 mmhg and/or msdbp ≥110 mmhg) * history of angioedema, drug-related or otherwise, as reported by the patient * type 1 or type 2 diabetes mellitus (according to the ada criteria) * history or evidence of a secondary form of hypertension, such as renal parenchymal hypertension, renovascular hypertension, coarctation of the aorta, primary hyperaldosteronism, cushing's disease, drug-induced hypertension, unilateral or bilateral renal artery stenosis, pheochromocytoma, polycystic kidney disease, etc. * history of angina pectoris, myocardial infarction, coronary bypass surgery, ischemic heart disease, surgical or percutaneous arterial intervention of any kind (coronary, carotid or peripheral intervention), stroke, tia (transient ischemic attack), carotid artery stenosis, aortic aneurysm or peripheral arterial disease

Keywords: hypertension, valsartan, lcz696